Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label studyLijuan Deng, Jun Zhu, Jianda Hu et al.|American Journal of Hematology|2023Cited by 18
Digitally driven surgical guide planning.Chenchen Zhang, Kai Zhang, Chi Song et al.|PubMed|2024Cited by 3